Illumina, Inc. (NASDAQ:ILMN) Shares Acquired by Schroder Investment Management Group

Schroder Investment Management Group raised its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 32.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 196,860 shares of the life sciences company's stock after buying an additional 48,263 shares during the period. Schroder Investment Management Group owned approximately 0.12% of Illumina worth $26,295,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. WCM Investment Management LLC raised its stake in shares of Illumina by 26.6% in the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock valued at $551,625,000 after acquiring an additional 867,673 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Illumina by 0.8% during the 4th quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company's stock worth $454,617,000 after purchasing an additional 27,618 shares during the period. Geode Capital Management LLC raised its position in Illumina by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company's stock valued at $354,933,000 after purchasing an additional 48,018 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of Illumina by 40.5% in the 3rd quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company's stock valued at $282,735,000 after buying an additional 625,245 shares during the period. Finally, Norges Bank acquired a new position in shares of Illumina during the fourth quarter worth about $228,714,000. Institutional investors and hedge funds own 89.42% of the company's stock.

Remove Ads

Illumina Stock Performance

Shares of NASDAQ:ILMN traded down $0.71 on Monday, reaching $73.45. The company's stock had a trading volume of 5,170,567 shares, compared to its average volume of 2,234,328. Illumina, Inc. has a 52-week low of $69.55 and a 52-week high of $156.66. The stock has a market capitalization of $11.63 billion, a P/E ratio of -9.56, a PEG ratio of 1.60 and a beta of 1.38. The stock's 50-day moving average is $95.52 and its two-hundred day moving average is $124.59. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, sell-side analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Barclays reaffirmed an "underweight" rating on shares of Illumina in a report on Tuesday, March 11th. Guggenheim reduced their price objective on shares of Illumina from $170.00 to $150.00 and set a "buy" rating on the stock in a report on Friday, February 7th. Stephens reiterated an "overweight" rating and set a $156.00 target price on shares of Illumina in a research note on Tuesday, March 11th. HSBC cut Illumina from a "buy" rating to a "hold" rating and set a $100.00 price target on the stock. in a research note on Friday, February 28th. Finally, Robert W. Baird lowered their price objective on Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a research report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $140.65.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.